PBPK modeling of coproporphyrin I as an endogenous biomarker for drug interactions involving inhibition of hepatic OATP1B1 and OATP1B3
T Yoshikado, K Toshimoto, K Maeda… - CPT …, 2018 - Wiley Online Library
The aim of the present study was to establish a physiologically based pharmacokinetic (PBPK)
model for coproporphyrin I (CP‐I), a biomarker supporting the prediction of drug‐drug …
model for coproporphyrin I (CP‐I), a biomarker supporting the prediction of drug‐drug …
Comprehensive PBPK model of rifampicin for quantitative prediction of complex drug‐drug interactions: CYP3A/2C9 induction and OATP inhibition effects
R Asaumi, K Toshimoto, Y Tobe… - CPT …, 2018 - Wiley Online Library
This study aimed to construct a physiologically based pharmacokinetic (PBPK) model of
rifampicin that can accurately and quantitatively predict complex drug‐drug interactions (DDIs) …
rifampicin that can accurately and quantitatively predict complex drug‐drug interactions (DDIs) …
A clinical quantitative evaluation of hepatobiliary transport of [11C] dehydropravastatin in humans using positron emission tomography
…, T Yamanaga, Y Wada, T Miyake, K Toshimoto… - Drug Metabolism and …, 2018 - ASPET
Various positron emission tomography (PET) probes have been developed to assess in
vivo activities in humans of drug transporters, which aid in the prediction of pharmacokinetic …
vivo activities in humans of drug transporters, which aid in the prediction of pharmacokinetic …
Comparison of methods for estimating unbound intracellular-to-medium concentration ratios in rat and human hepatocytes using statins
T Yoshikado, K Toshimoto, T Nakada, K Ikejiri… - Drug Metabolism and …, 2017 - ASPET
It is essential to estimate concentrations of unbound drugs inside the hepatocytes to predict
hepatic clearance, efficacy, and toxicity of the drugs. The present study was undertaken to …
hepatic clearance, efficacy, and toxicity of the drugs. The present study was undertaken to …
Physiologically‐based pharmacokinetic modeling analysis for quantitative prediction of renal transporter–mediated interactions between metformin and cimetidine
K Nishiyama, K Toshimoto, W Lee… - CPT …, 2019 - Wiley Online Library
Metformin is an important antidiabetic drug and often used as a probe for drug–drug interactions
( DDIs ) mediated by renal transporters. Despite evidence supporting the inhibition of …
( DDIs ) mediated by renal transporters. Despite evidence supporting the inhibition of …
Analysis of nonlinear pharmacokinetics of a highly albumin-bound compound: contribution of albumin-mediated hepatic uptake mechanism
Y Fukuchi, K Toshimoto, T Mori, K Kakimoto… - Journal of …, 2017 - Elsevier
The cause of nonlinear pharmacokinetics (PK) (more than dose-proportional increase in
exposure) of a urea derivative under development (compound A: anionic compound [pKa: 4.4]; …
exposure) of a urea derivative under development (compound A: anionic compound [pKa: 4.4]; …
[HTML][HTML] Virtual clinical studies to examine the probability distribution of the AUC at target tissues using physiologically-based pharmacokinetic modeling: application to …
K Toshimoto, A Tomaru, M Hosokawa… - Pharmaceutical …, 2017 - Springer
Purpose To establish a physiologically-based pharmacokinetic (PBPK) model for analyzing
the factors associated with side effects of irinotecan by using a computer-based virtual …
the factors associated with side effects of irinotecan by using a computer-based virtual …
[HTML][HTML] Cluster Gauss–Newton method: an algorithm for finding multiple approximate minimisers of nonlinear least squares problems with applications to parameter …
Parameter estimation problems of mathematical models can often be formulated as nonlinear
least squares problems. Typically these problems are solved numerically using iterative …
least squares problems. Typically these problems are solved numerically using iterative …
Physiologically based pharmacokinetic modeling of bosentan identifies the saturable hepatic uptake as a major contributor to its nonlinear pharmacokinetics
M Sato, K Toshimoto, A Tomaru, T Yoshikado… - Drug Metabolism and …, 2018 - ASPET
Bosentan is a substrate of hepatic uptake transporter organic anion–transporting
polypeptides (OATPs), and undergoes extensive hepatic metabolism by cytochrome P450 (P450), …
polypeptides (OATPs), and undergoes extensive hepatic metabolism by cytochrome P450 (P450), …
Strategies to improve the prediction accuracy of hepatic intrinsic clearance of three antidiabetic drugs: application of the extended clearance concept and …
…, S Aoyama, K Maeda, K Ito, K Toshimoto… - European Journal of …, 2018 - Elsevier
The antidiabetic drugs glibenclamide, repaglinide, and nateglinide are well-known substrates
for hepatic uptake transporters of the organic anion transporting polypeptide (OATP) family …
for hepatic uptake transporters of the organic anion transporting polypeptide (OATP) family …